Hepatic

Mouse studies suggest AMPK activators could help treat non-alcoholic fatty liver disease (NAFLD). In mice, liver-specific expression of an overactive human mutant AMPK decreased glucose production and fatty acid synthesis compared with no transgene expression. In a mouse model of diet-induced NAFLD, liver-specific expression of the mutant AMPK decreased hepatic triglyceride levels. Next steps could include testing AMPK activators in other models of NAFLD.

Betagenon AB has the AMPK activator O304 in Phase II testing for Type II diabetes and Phase I testing for obesity...